Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)

Summary

To evaluate the efficacy and safety of fingolimod 0.5mg versus placebo in patients with suspected acute demyelinating optic neuritis (ADON) receiving standard steroid treatment

Timeline

Start

2013-08

Primary completion

2014-05

Completion

2014-05

Outcome

Outcome not reported

Stopped: “Discontinuation of this study was based on Novartis decision to discontinue development of fingolimod for the treatment of ADON”

Drugs

Indications